Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27828537 | 1.00 | TDP1 (0.44) | TDP1TSHRTRPV1 | |
| SCHEMBL15496479 | 0.85 | TDP1 (0.57) | TDP1TSHRTRPV1 | |
| SCHEMBL10509917 | 0.84 | TDP1 (0.46) | TDP1TSHRTRPV1 | |
| SCHEMBL10507358 | 0.84 | TDP1 (0.46) | TDP1TSHRTRPV1 | |
| SCHEMBL10733105 | 0.84 | TDP1 (0.46) | TDP1TSHRTRPV1 | |
| SCHEMBL10511032 | 0.84 | TDP1 (0.46) | TDP1TSHRTRPV1 | |
| SCHEMBL10509129 | 0.84 | TDP1 (0.46) | TDP1TSHRTRPV1 | |
| SCHEMBL10508529 | 0.84 | TDP1 (0.46) | TDP1TSHRTRPV1 | |
| SCHEMBL10738641 | 0.84 | TDP1 (0.46) | TDP1TSHRTRPV1 | |
| SCHEMBL17748350 | 0.84 | TDP1 (0.46) | TDP1TSHRTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2282773-B2 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC (US) | 2025-03-05 | — | — | EP | claimed |
| EP-3513794-A2 | FUCOSE ANALOGS FOR INHIBITION OF PROTEIN FUCOSYLATION IN VIVO | Seattle Genetics, Inc. (US) | 2019-07-24 | — | — | EP | claimed |
| EP-2282773-B1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEATTLE GENETICS INC (US) | 2014-01-15 | — | — | EP | claimed |
| US-20120183997-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEATTLE GENETICS, INC. (US) | 2012-07-19 | — | — | US | claimed |
| US-8163551-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEATTLE GENETICS, INC. (US) | 2012-04-24 | — | — | US | claimed |
| EP-2282773-B2 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20230055475-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC (US) | 2023-02-23 | — | — | US | disclosed |
| US-11319526-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEAGEN INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11033561-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | SEAGEN INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200061091-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | SEATTLE GENETICS, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| US-10443035-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEATTLE GENETICS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190276796-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC. | 2019-09-12 | — | — | US | disclosed |
| EP-2608796-A2 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | Seattle Genetics, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130129784-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | SEATTLE GENETICS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120183997-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEATTLE GENETICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-8163551-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEATTLE GENETICS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| WO-2012019165-A2 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | SEATTLE GENETICS, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| EP-2282773-A2 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | Seattle Genetics, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20090317869-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEATTLE GENETICS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009135181-A2 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEATTLE GENETICS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055475-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | FUT5, FUCA2, FCGR3B | TDP1 4741/4885TSHR 1665/4885TRPV1 4880/4885 |
| US-10443035-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | FUT5, FUCA2, FCGR3B | TDP1 4741/4885TSHR 1665/4885TRPV1 4880/4885 |
| US-20200061091-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | FUCA1, FUCA2, FUT4 | TDP1 4730/4885TSHR 3062/4885TRPV1 4885/4885 |
| US-11033561-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | FUCA1, FUCA2, FUT4 | TDP1 4730/4885TSHR 3062/4885TRPV1 4885/4885 |
| US-20130129784-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | FUCA1, FUCA2, FUT4 | TDP1 4730/4885TSHR 3062/4885TRPV1 4885/4885 |
| US-20190276796-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | FUT5, FUCA2, FCGR3B | TDP1 4741/4885TSHR 1665/4885TRPV1 4880/4885 |
| US-11319526-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | FUT5, FUCA2, FCGR3B | TDP1 4741/4885TSHR 1665/4885TRPV1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.